This study examines changes in androgen profiles in men exposed to tildacerfont, a non-steroidal, once-daily oral CRF1 receptor antagonist, with the goal of gaining understanding of how CRF1 antagonism in men with CAH may impact gonadal Leydig cell function. This evidence concerns the gene CRHR1 and congenital adrenal hyperplasia.